Neuromodulation最新文献_第7页

30. Is that a bellows I see? Setting up a new sacral neuromodulation service in Calgary, Alberta, the first foray 30.。我看到的是风箱吗？在阿尔伯塔省的卡尔加里建立了一个新的骶神经调节服务，这是第一次尝试

IF 3.2 3区医学

Neuromodulation Pub Date : 2025-06-01 DOI: 10.1016/j.neurom.2025.03.032

A. Rowan, B. Hoffarth-Palchewich, S. Kim-Fine

引用次数: 0

Accelerated Transcutaneous Auricular Vagus Nerve Stimulation for Inpatient Depression and Anxiety: The iWAVE Open Label Pilot Trial 加速经皮耳迷走神经刺激治疗住院患者抑郁和焦虑：iWAVE开放标签试点试验

IF 3.2 3区医学

Neuromodulation Pub Date : 2025-06-01 DOI: 10.1016/j.neurom.2025.02.003

Christopher W. Austelle MD , Stewart S. Cox MD, PhD , Dillon J. Connolly BS , Brenna Baker Vogel BS , Xiaolong Peng PhD , Kristin Wills BS , Falon Sutton BS , Katherine B. Tucker BS , Ethan Ashley MD , Andrew Manett MD , Bernadette Cortese PhD , Edward Baron Short MD , Bashar W. Badran PhD

{"title":"Accelerated Transcutaneous Auricular Vagus Nerve Stimulation for Inpatient Depression and Anxiety: The iWAVE Open Label Pilot Trial","authors":"Christopher W. Austelle MD , Stewart S. Cox MD, PhD , Dillon J. Connolly BS , Brenna Baker Vogel BS , Xiaolong Peng PhD , Kristin Wills BS , Falon Sutton BS , Katherine B. Tucker BS , Ethan Ashley MD , Andrew Manett MD , Bernadette Cortese PhD , Edward Baron Short MD , Bashar W. Badran PhD","doi":"10.1016/j.neurom.2025.02.003","DOIUrl":"10.1016/j.neurom.2025.02.003","url":null,"abstract":"<div><h3>Introduction</h3><div>Brain stimulation is not a common inpatient psychiatric treatment; however, there are an increasing number of neuromodulation treatments approved for psychiatric indications. Noninvasive techniques, such as transcutaneous auricular vagus nerve stimulation (taVNS), are promising and should be investigated in this novel setting. This study evaluates the safety and feasibility of taVNS on the inpatient psychiatric unit and preliminarily explores efficacy for comorbid depression and anxiety.</div></div><div><h3>Materials and Methods</h3><div>Ten adult patients (five women, mean age ± SD, 35.60 ± 19.14 years) admitted to the inpatient psychiatric unit with comorbid depression and anxiety participated in this open-label safety and feasibility trial. Patients were randomized to receive one of two taVNS dosing approaches: 1) three taVNS sessions on three consecutive days (nine sessions total) (<em>n</em> = 5) or 2) nine taVNS sessions in one day (<em>n</em> = 5). Each day, we assessed depression, using the Patient Health Questionnaire (PHQ-9) and Beck Depression Inventory (BDI), and anxiety, using the Generalized Anxiety Disorder-7 (GAD-7) and Beck Anxiety Inventory (BAI).</div></div><div><h3>Results</h3><div>Both taVNS dosing approaches were safe and feasible in this novel setting. There were no serious adverse events, and we observed a low rate of minor adverse effects, which was similar across treatment conditions. Regardless of condition, stimulation significantly reduced GAD-7 (mean reduction ± SD, −5.90 to 6.87, <em>p</em> < 0.05), BAI (−9.40 ± 10.52, <em>p</em> < 0.05), PHQ-9 (−6.00 ± 7.57, <em>p</em> < 0.05), and BDI (−11.00 ± 11.59, <em>p</em> < 0.05) final scores compared with baseline. There was not a significant difference in clinical response between treatment conditions.</div></div><div><h3>Discussion</h3><div>In this open label study, taVNS significantly decreased depression and anxiety symptoms in patients admitted to the inpatient unit. The small sample size in this trial limited our ability to characterize patient characteristics that may drive response. However, our results suggest taVNS may be an effective adjunct to inpatient psychiatric treatment and should continue to be studied in this setting.</div></div><div><h3>Clinical Trial Registration</h3><div>The <span><span>Clinicaltrials.gov</span><svg><path></path></svg></span> registration number for the study is NCT05791383.</div></div>","PeriodicalId":19152,"journal":{"name":"Neuromodulation","volume":"28 4","pages":"Pages 672-681"},"PeriodicalIF":3.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

6. Externally powered SCS at C2 for refractory neuropathic occipital and facial pain 6. 外部供电SCS在C2治疗难治性神经性枕部和面部疼痛

IF 3.2 3区医学

Neuromodulation Pub Date : 2025-06-01 DOI: 10.1016/j.neurom.2025.03.008

M. Macdonald, H. Bedran, E. Pereira, M. Tavakkoli

引用次数: 0

38. Patient experience of closed loop multi-waveform spinal cord stimulation 38. 闭环多波形脊髓刺激的患者体验

IF 3.2 3区医学

Neuromodulation Pub Date : 2025-06-01 DOI: 10.1016/j.neurom.2025.03.040

A. Gulve, V. Goodridge, S. Copley

引用次数: 0

40. Peripheral nerve stimulation using fast acting subperception therapy for nummular headache 40. 快效亚知觉疗法治疗麻木性头痛的外周神经刺激